Adimmune Corp (4142) - Net Assets
Based on the latest financial reports, Adimmune Corp (4142) has net assets worth NT$4.85 Billion TWD (≈ $152.90 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$8.38 Billion ≈ $264.03 Million USD) and total liabilities (NT$3.53 Billion ≈ $111.13 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 4142 intangible-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$4.85 Billion |
| % of Total Assets | 57.91% |
| Annual Growth Rate | 6.44% |
| 5-Year Change | -16.1% |
| 10-Year Change | 50.93% |
| Growth Volatility | 36.43 |
Adimmune Corp - Net Assets Trend (2007–2024)
This chart illustrates how Adimmune Corp's net assets have evolved over time, based on quarterly financial data. See 4142 defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Adimmune Corp (2007–2024)
The table below shows the annual net assets of Adimmune Corp from 2007 to 2024. For live valuation and market cap data, see 4142 stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | NT$5.56 Billion ≈ $175.22 Million |
-3.74% |
| 2023-12-31 | NT$5.78 Billion ≈ $182.03 Million |
-11.72% |
| 2022-12-31 | NT$6.54 Billion ≈ $206.20 Million |
+1.75% |
| 2021-12-31 | NT$6.43 Billion ≈ $202.66 Million |
-2.96% |
| 2020-12-31 | NT$6.63 Billion ≈ $208.84 Million |
+73.27% |
| 2019-12-31 | NT$3.83 Billion ≈ $120.53 Million |
+106.09% |
| 2018-12-31 | NT$1.86 Billion ≈ $58.48 Million |
-20.99% |
| 2017-12-31 | NT$2.35 Billion ≈ $74.02 Million |
-24.09% |
| 2016-12-31 | NT$3.09 Billion ≈ $97.51 Million |
-16.01% |
| 2015-12-31 | NT$3.68 Billion ≈ $116.09 Million |
-17.52% |
| 2014-12-31 | NT$4.47 Billion ≈ $140.75 Million |
+38.01% |
| 2013-12-31 | NT$3.24 Billion ≈ $101.99 Million |
-13.51% |
| 2012-12-31 | NT$3.74 Billion ≈ $117.92 Million |
+4.02% |
| 2011-12-31 | NT$3.60 Billion ≈ $113.37 Million |
-11.43% |
| 2010-12-31 | NT$4.06 Billion ≈ $127.99 Million |
+7.85% |
| 2009-12-31 | NT$3.77 Billion ≈ $118.67 Million |
+18.86% |
| 2008-12-31 | NT$3.17 Billion ≈ $99.84 Million |
+64.67% |
| 2007-12-31 | NT$1.92 Billion ≈ $60.63 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Adimmune Corp's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 23524100000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | NT$205.41 Million | 3.93% |
| Common Stock | NT$4.30 Billion | 82.08% |
| Other Comprehensive Income | NT$195.27 Million | 3.73% |
| Other Components | NT$536.96 Million | 10.26% |
| Total Equity | NT$5.23 Billion | 100.00% |
Adimmune Corp Competitors by Market Cap
The table below lists competitors of Adimmune Corp ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Coincheck Group N.V. Ordinary Shares
NASDAQ:CNCK
|
$232.44 Million |
|
SHIPPING CORPORATION OF INDIA LAND
NSE:SCILAL
|
$232.48 Million |
|
Zalaris ASA
OL:ZAL
|
$232.62 Million |
|
Ajinomoto Malaysia Bhd
KLSE:2658
|
$232.63 Million |
|
Jikai Equipment Manufacturing Co Ltd
SHE:002691
|
$232.35 Million |
|
GDEV Inc.
NASDAQ:GDEV
|
$232.33 Million |
|
Libra Insurance Company Ltd
TA:LBRA
|
$232.31 Million |
|
BT Group Plc
LSE:BT-A
|
$232.23 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Adimmune Corp's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 5,474,500,000 to 5,232,721,000, a change of -241,779,000 (-4.4%).
- Net loss of 242,750,000 reduced equity.
- Other comprehensive income increased equity by 10,550,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$-242.75 Million | -4.64% |
| Other Comprehensive Income | NT$10.55 Million | +0.2% |
| Other Changes | NT$7.97 Million | +0.15% |
| Total Change | NT$- | -4.42% |
Book Value vs Market Value Analysis
This analysis compares Adimmune Corp's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.41x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 1.53x to 1.41x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2007-12-31 | NT$11.47 | NT$17.50 | x |
| 2008-12-31 | NT$18.89 | NT$17.50 | x |
| 2009-12-31 | NT$22.45 | NT$17.50 | x |
| 2010-12-31 | NT$23.99 | NT$17.50 | x |
| 2011-12-31 | NT$20.71 | NT$17.50 | x |
| 2012-12-31 | NT$20.01 | NT$17.50 | x |
| 2013-12-31 | NT$16.65 | NT$17.50 | x |
| 2014-12-31 | NT$19.71 | NT$17.50 | x |
| 2015-12-31 | NT$13.89 | NT$17.50 | x |
| 2016-12-31 | NT$11.68 | NT$17.50 | x |
| 2017-12-31 | NT$8.53 | NT$17.50 | x |
| 2018-12-31 | NT$6.97 | NT$17.50 | x |
| 2019-12-31 | NT$10.04 | NT$17.50 | x |
| 2020-12-31 | NT$15.40 | NT$17.50 | x |
| 2021-12-31 | NT$14.31 | NT$17.50 | x |
| 2022-12-31 | NT$14.32 | NT$17.50 | x |
| 2023-12-31 | NT$12.99 | NT$17.50 | x |
| 2024-12-31 | NT$12.41 | NT$17.50 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Adimmune Corp utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -4.64%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -15.59%
- • Asset Turnover: 0.18x
- • Equity Multiplier: 1.62x
- Recent ROE (-4.64%) is above the historical average (-9.02%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2007 | -1.78% | -15.34% | 0.10x | 1.11x | NT$-226.75 Million |
| 2008 | -2.29% | -39.73% | 0.04x | 1.32x | NT$-389.35 Million |
| 2009 | 15.63% | 42.99% | 0.24x | 1.52x | NT$212.21 Million |
| 2010 | 3.97% | 19.32% | 0.15x | 1.33x | NT$-244.94 Million |
| 2011 | -13.17% | -162.32% | 0.05x | 1.57x | NT$-829.07 Million |
| 2012 | -16.13% | -155.92% | 0.06x | 1.60x | NT$-977.96 Million |
| 2013 | -18.55% | -145.00% | 0.08x | 1.69x | NT$-924.16 Million |
| 2014 | -14.64% | -127.87% | 0.08x | 1.40x | NT$-1.03 Billion |
| 2015 | -22.15% | -261.78% | 0.05x | 1.58x | NT$-1.10 Billion |
| 2016 | -20.68% | -98.13% | 0.09x | 2.36x | NT$-883.21 Million |
| 2017 | -36.03% | -135.08% | 0.10x | 2.72x | NT$-971.15 Million |
| 2018 | -37.61% | -75.13% | 0.14x | 3.46x | NT$-782.12 Million |
| 2019 | -7.70% | -21.60% | 0.20x | 1.80x | NT$-645.21 Million |
| 2020 | 19.65% | 66.41% | 0.22x | 1.34x | NT$609.63 Million |
| 2021 | 0.70% | 2.62% | 0.20x | 1.30x | NT$-571.82 Million |
| 2022 | 4.75% | 12.92% | 0.25x | 1.49x | NT$-321.40 Million |
| 2023 | -11.69% | -35.85% | 0.19x | 1.73x | NT$-1.19 Billion |
| 2024 | -4.64% | -15.59% | 0.18x | 1.62x | NT$-766.02 Million |
Industry Comparison
This section compares Adimmune Corp's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,605,275,000
- Average return on equity (ROE) among peers: 6.79%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Adimmune Corp (4142) | NT$4.85 Billion | -1.78% | 0.73x | $232.40 Million |
| Apex Biotechnology Corp (1733) | $1.75 Billion | 11.53% | 0.52x | $92.11 Million |
| Sinphar Pharmaceutical Co Ltd (1734) | $1.32 Billion | 9.26% | 0.78x | $190.85 Million |
| Panion & BF Biotech Inc (1760) | $1.93 Billion | 5.40% | 0.53x | $161.80 Million |
| Chunghwa Chemical Synthesis & Biotech Co Ltd (1762) | $2.50 Billion | 21.29% | 0.26x | $85.54 Million |
| SYN-Tech Chem & Pharm Co Ltd (1777) | $969.06 Million | 16.12% | 0.26x | $101.71 Million |
| Level Biotechnology (3118) | $542.40 Million | 10.78% | 0.50x | $31.95 Million |
| GenMont Biotech Inc (3164) | $737.87 Million | 20.00% | 0.85x | $44.44 Million |
| Medigen Biotechnology (3176) | $3.46 Billion | -15.61% | 0.30x | $146.59 Million |
| Sagittarius Life Science (3205) | $588.38 Million | -12.60% | 0.26x | $112.36 Million |
| Genovate Biotechnology Co Ltd (4130) | $2.25 Billion | 1.74% | 0.18x | $112.45 Million |
About Adimmune Corp
Adimmune Corporation engages in the development, manufacture, and distribution of vaccines and other biological products in Taiwan, the United States, China, and internationally. The company offers AdimFlu-S, a quadrivalent influenza vaccine; suspensions for injection influenza vaccines; and tetanus toxoid alum precipitated product for the prevention of tetanus after injury. It also develops Adim… Read more